Creative Medical Tech Faces 2025 Losses Amid FDA Trials
Creative Medical Technology outlines 2025 losses, trials
Creative Medical Technology’s 2025 report shows an operating loss, modest cash of about $7.2M, and minimal revenue, while advancing FDA-cleared trials, Fast Track CELZ-201-DDT, and iPSC/AI partnerships targeting diabetes, back pain and other regenerative indications.
Creative Medical Technology reported significant 2025 operating losses with modest cash reserves of $7.2 million and minimal revenue. However, the company is advancing FDA-cleared trials including Fast Track CELZ-201-DDT and iPSC/AI partnerships targeting diabetes, back pain, and other regenerative medicine indications.
Original Article
Read full article on sourceExplore More
Related News
JAPAN-CLIMATE-ENERGY-TECHNOLOGY-ENVIRONMENT • Channels Television
Channels Television · 2026.04.05
Mustard Debate: Tradition vs Technology
Devdiscourse · 2026.04.05
read, write and learn about any technology
HackerNoon · 2026.04.05
Technology and the New Logic of Growth
Daily Good Morning Kashmir · 2026.04.05
Investment Opportunities in the AI Technology Cycle
2026.04.05
Basic Space Technology: Basic Space Technology Summer Course completed
2026.04.04